Conclusion of the Blog Series: Innovations in Controlled Drug Release

Over the past few weeks, we have explored the fascinating world of patents related to controlled and modified drug release through our eight-part blog series. This journey has taken us from the extended release of pyridostigmine and atomoxetine to the innovative formulations of gamma-hydroxybutyrate. 🚀💊

Each entry provided valuable insights into the advancements in Cellets technology and its impact on drug administration. We examined how highly lipophilic physiologically active substances and pulsatile release mechanisms are poised to revolutionize therapeutic approaches. 🌟

The insights gained from this series underscore the importance of these technologies in enhancing patient outcomes. Not only do they improve compliance, but they also enable targeted therapies tailored to the unique needs of each patient.

Here’s a recap of the blog posts featured in the series:

1. 1. 1. Patent on Extended Release Compositions Comprising Pyridostigmine
         Posted on: Oct 24, 2024
      2. Patent on Extended-Release Compositions Comprising Atomoxetine
         Posted on: Oct 31, 2024
      3. Patent on Modified Release Gamma-Hydroxybutyrate Formulations
         Posted on: Nov 07, 2024
      4. Patent on Methods of Administering Gamma-Hydroxybutyrate
         Posted on: Nov 14, 2024
      5. Highly Lipophilic Physiologically Active Substances – Controlled Release
         Posted on: Nov 21, 2024
      6. Modified-Release Gamma-Hydroxybutyrate – a pellet technologies Formulation
         Posted on: Nov 28, 2024
      7. Patent on Pulsatile Release Caffeine Formulation – a pellet technologies Formulation
         Posted on: Dec 05, 2024
      8. Patent on Packaged Modified Release Gamma-Hydroxybutyrate
         Posted on: Dec 12, 2024
      9. Patent on gamma-hydroxybutyrate compositions having improved pharmacokinetics
         Posted on: Dec 19, 2024
      10. Patent on pharmaceutical compositions and methods for treating hyperhidrosis
          Posted on: Jan 02, 2025

We extend our heartfelt gratitude to everyone who has accompanied us on this enlightening journey. We look forward to sharing more insights and innovations in the field of drug development in the future. Stay tuned for our upcoming content and follow us on LinkedIn! 📅✨